Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Convertible Debt (2016 - 2021)

Northwest Biotherapeutics' Convertible Debt history spans 11 years, with the latest figure at $300000.0 for Q4 2021.

  • Quarterly results put Convertible Debt at $300000.0 for Q4 2021, changed 0.0% from a year ago — trailing twelve months through Dec 2021 was $300000.0 (changed 0.0% YoY), and the annual figure for FY2021 was $300000.0, changed 0.0%.
  • Convertible Debt for Q4 2021 was $300000.0 at Northwest Biotherapeutics, roughly flat from $300000.0 in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $6.6 million in Q1 2018 to a low of $240000.0 in Q1 2020.
  • The 4-year median for Convertible Debt is $5.1 million (2017), against an average of $3.3 million.
  • The sharpest move saw Convertible Debt crashed 49.61% in 2017, then rose 20.27% in 2018.
  • Year by year, Convertible Debt stood at $6.0 million in 2017, then fell by 13.68% to $5.2 million in 2018, then plummeted by 94.22% to $300000.0 in 2020, then changed by 0.0% to $300000.0 in 2021.
  • According to Business Quant data, Convertible Debt over the past three periods came in at $300000.0, $300000.0, and $315000.0 for Q4 2021, Q4 2020, and Q3 2020 respectively.